İrem YANATMA, Gülbahar SARAÇ, Hülya CENK, Hacer VURAL KARATOPRAK

Bullous dermatosis in the southeastern of Turkey: A study of 125 cases

Aim: Autoimmune bullous diseases occur when antibodies against proteins such as desmosomes and hemidesmosomes cause separation in the skin. Detailed epidemiological studies examining these diseases are limited in our country. We aim to contribute to the demographic, clinical, and treatment data on bullous diseases from an important geographic region of our country. Materials and Methods: The data of 125 cases who were followed up with a diagnosis of bullous disease between 2006 and 2019 were evaluated retrospectively. Socio-demographic characteristics, diagnoses, age and duration of disease onset, clinical findings, accompanying systemic diseases, treatments given, and side effects related to treatment were recorded. Results: 57.6% of the patients (72 people) were diagnosed as pemphigus, 31.2% (39 people) bullous pemphigoid (BP), 8% (10 people) dermatitis herpetiformis (DH), 3.2% (4 people) linear Ig A dermatosis ( LAD). BP patients were found to be significantly older than the other patients (p = 0.002). While pemphigus, BP, and LAD were more common in women, 70% of DH patients were men. Malignancy was detected in 2.8% of pemphigus patients and 5.1% of BP patients. Accompanying autoimmune disease was found in 9.7% of pemphigus patients, 17.9% of BP patients, and 20% of DH patients. The only systemic steroid was used in 20.8% of pemphigus patients, and azathioprine as a conventional agent was used in 76.4% with systemic steroid. Rituximab was started in patients who did not respond to therapy. The systemic steroid was used in 35.9% of BP patients, and azathioprine with systemic steroid was used in 43.6% of BP patients. Doxycycline was added to the treatment in 41% of the patients. Rituximab was used in 5 (12.8%) patients. Conclusion: Since our study is the first data obtained on bullous diseases from the southeastern Anatolia region, it is useful for the literature in terms of providing a basis for future studies. İrem

PDF

___

1. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Archives of dermatological research 2015; 307: 291-8.
2. Uzun S, Durdu M, Akman A et al. Pemphigus in the Mediterranean region of Turkey: a study of 148 cases. International journal of dermatology 2006; 45: 523-8.
3. Daye M, Mevlitoğlu İ, Esener S. Konya ilinde büllöz hastalıklar: 93 olgu üzerine bir çalışma. Turkderm 2013; 47: 200-4.
4. Jung M, Kippes W, Messer G et al. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. Journal of the American Academy of Dermatology 1999; 41: 266-8.
5. Marazza G, Pham HC, Schärer L et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. The British journal of dermatology 2009; 161: 861-8.
6. Bertram F, Bröcker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009; 7: 434-40.
7. Mendes FB, Hissa-Elian A, Abreu MA, Gonçalves VS. Review: dermatitis herpetiformis. An Bras Dermatol 2013; 88: 594-9.
8. Parker SR, MacKelfresh J. Autoimmune blistering diseases in the elderly. Clinics in dermatology 2011; 29: 69-79.
9. Balestri R, Magnano M, La Placa M et al. Malignancies in bullous pemphigoid: a controversial association. The Journal of dermatology 2016; 43: 125-33.
10. Lindelöf B, Islam N, Eklund G, Åfors L. Pemphigoid and cancer. Archives of dermatology 1990; 126: 66-8.
11. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Archives of dermatology 1993; 129: 883-6.
12. Ogawa H, Sakuma M, Morioka S et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995; 9: 136-41.
13. Karabay EA, Çerman AA, Altunay İ K. Evaluation of Comorbidities in Patients with Autoimmune Bullous Diseases: A Retrospective Study. Sisli Etfal Hastanesi tip bulteni 2018; 52: 302- 6.
14. Caproni M, Cardinali C, Renzi D et al. Tissue transglutaminase antibody assessment in dermatitis herpetiformis. The British journal of dermatology 2001; 144: 196-7.
15. Alonso-Llamazares J, Gibson LE, Rogers RS, 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. International journal of dermatology 2007; 46: 910-9.
16. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2011; 9: 844-56; quiz 57.
17. Fuertes I, Mascaró JM, Bombí JA, Iranzo P. [A retrospective study of clinical, histological, and immunological characteristics in patients with dermatitis herpetiformis. The experience of Hospital Clinic de Barcelona, Spain, between 1995 and 2010 and a review of the literature]. Actas Dermosifiliogr 2011; 102: 699- 705.
18. Akarsu S, Özbağçivan Ö, Dolaş N, Aktan Ş. Possible triggering factors and comorbidities in newly diagnosed autoimmune bullous diseases. Turkish journal of medical sciences 2017; 47: 832-40.
19. Ingen-Housz-Oro S. [Dermatitis herpetiformis: a review]. Annales de dermatologie et de venereologie 2011; 138: 221-7.
20. Leshem YA, Katzenelson V, Yosipovitch G et al. Autoimmune diseases in patients with pemphigus and their first-degree relatives. International journal of dermatology 2011; 50: 827-31.
21. Huh WK, Tada J, Fujimoto W et al. Thyroid gland tumour, pemphigus foliaceus and myasthenia gravis in the daughter of a woman with myasthenia gravis. Clinical and experimental dermatology 2001; 26: 504-6.
22. Firooz A, Mazhar A, Ahmed AR. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. Journal of the American Academy of Dermatology 1994; 31: 434-7.
23. Ruocco V, Ruocco E, Lo Schiavo A et al. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clinics in dermatology 2013; 31: 374-81.
24. Brenner S, Tur E, Shapiro J et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. International journal of dermatology 2001; 40: 562-9.
25. Tükenmez Demirci G, Mansur AT, Aydıngöz İE. Risk factors in pemphigus. TURKDERM-Archieves of The Turkish Dermatology and Venerology 2011; 45: 140-5.
26. Murrell DF, Peña S, Joly P et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology 2020; 82: 575-85.e1.
27. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. The New England journal of medicine 2007; 357: 545-52.